(Q37118188)

English

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting

scientific article published on April 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

1 reference

Europe PubMed Central

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

5

object named as

W Martin Kast

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

author name string

Andrew Gray

1

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Adam B Raff

2

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Maurizio Chiriva-Internati

3

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Si-Yi Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

publication date

1 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Immunological Reviews

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

222

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

316-327

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Therapeutic dendritic cell vaccination of patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immune resistance orchestrated by the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immunosuppressive networks in the tumour environment and their therapeutic relevance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

CD8+ T-cell memory in tumor immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Tumors hamper the immunogenic competence of CD4+ T cell-directed dendritic cell vaccination

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Tregs and rethinking cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Premalignant lesions as targets for cancer vaccines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immune responses in the draining lymph nodes against cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Tumor escape mechanisms in prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Combinations of anticancer drugs and immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Prophylactic cancer vaccines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Thymic output in aged mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Therapeutic vaccination for HPV induced cervical cancers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Mechanisms used by human papillomaviruses to escape the host immune response.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Cancer vaccines: moving beyond current paradigms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Contribution of oncoproteomics to cancer biomarker discovery

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Identifiers

10.1111/J.1600-065X.2008.00605.X

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37118188&oldid=2139651265"